

Date: 5 September, 2018

Tel: +44 (0)161 276 4452
Email: ABoulton@med.miami.edu

Dr Sigurjon Lydsson
CEO & Co founder
Medilync
Iceland

Dear Dr Lydsson

Re: Grant application to European Commission

I am happy to lend strong support to your grant to the European Commission to promote the use of Cloudlync through the Insulync app. At the present time there is a global epidemic of type 2 diabetes and in this electronic age, there is a need to use this new technology in the management and monitoring of those people with diabetes. There is certainly therefore a need for developments such as yours which should provide a high quality and patient-centred design in medical device innovation and development. I was pleased to learn from my former PhD student and now professorial colleague in Los Angeles, Prof David Armstrong, that he has evaluated technology from your company and feels that this provides enormous promise to improve day-to-day compliance with treatments used in diabetes.

I do hope that you are successful in your grant application and look forward to the important developments that will no doubt result from your studies.

With kind regards.

Yours sincerely



Andrew JM Boulton, MD, DSc (Hon), FACP, FICP, FRCP
President, Worldwide Initiative for Diabetes Education.
Chair, Alliance for European Diabetes Research (EURADIA)
President-Elect, International Diabetes Federation.
Professor of Medicine, University of Manchester and
Visiting Professor, University of Miami, FL,
Consultant Physician, Manchester Royal Infirmary.
Immediate Past-President, European Association for the Study of Diabetes

www.mft.nhs.uk

Incorporating:

Altrincham Hospital • Manchester Royal Eye Hospital • Manchester Royal Infirmary • Royal Manchester Children's Hospital •
Saint Mary's Hospital • Trafford General Hospital • University Dental Hospital of Manchester • Wythenshawe Hospital •
Withington Community Hospital • Community Services